# Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries

> **NCT03631056** · — · APPROVED_FOR_MARKETING · sponsor: **Humacyte, Inc.**

## Conditions studied

- Vascular System Injuries

## Interventions

- **BIOLOGICAL:** Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)

## Key facts

- **NCT ID:** NCT03631056
- **Lead sponsor:** Humacyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631056, "Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03631056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*